Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of [alpha]-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study

Introduction To investigate canagliflozin-induced changes in postprandial total glucagon-like peptide 1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) levels in patients with type 2 diabetes mellitus (T2DM). Methods Forty-five patients with T2DM who had inadequate glycemic control (g...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Diabetes therapy 2019-12, Vol.10 (6), p.2045
Hauptverfasser:	Osonoi, Takeshi, Tamasawa, Atsuko, Osonoi, Yusuke, Ofuchi, Kensuke, Katoh, Makoto, Saito, Miyoko
Format:	Artikel
Sprache:	eng
Schlagworte:	Diabetes therapy Dosage and administration Drug therapy Enzyme inhibitors Pharmacology, Experimental Physiological aspects Type 2 diabetes
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!